This article describes a previously unreported mutation at position 210 (C210T) of the mitochondrial large subunit ribosomal RNA (mtLSUrRNA) gene of Pneumocystis jirovecii, which led to a false-negative result of a real-time polymerase chain reaction (PCR) assay. Since the aforementioned real-time PCR assay is widely used in France, a French multicenter study was conducted to estimate the mutation frequency and its potential impact on the routine diagnosis of Pneumocystis pneumonia (PCP). Through analysis of data obtained from eight centers, the mutation frequency was estimated at 0.28%. This low frequency should not call into question the routine use of this PCR assay.
Introduction
Pneumocystis pneumonia (PCP) diagnosis is based on direct detection of Pneumocystis jirovecii (P. jirovecii) in pulmonary specimens by microscopy and polymerase chain reaction (PCR) assays. The use of PCR assays has improved the sensitivity of P. jirovecii detection, specifically in pulmonary samples with low fungal burdens. 1, 2 A real-time PCR assay amplifying the mitochondrial large subunit ribosomal RNA (mtLSUrRNA) gene of P. jirovecii with a TaqMan R Minor Groove Binder (MGB) probe was previously described. 3, 4 We have used it for routine PCP diagnosis for the past 6 years in Brest University Hospital, representing about 3000 runs of amplification and the diagnosis of about 240 PCP cases. Each run includes a positive control (plasmid containing a mtLSUrRNA gene insert) and two negative controls [negative control of extraction, negative control of the amplification run (ultrapure distilled water)]. The cellular quality of BAL specimens is controlled using amplification of a single copy human gene (TaqMan R RNase P Control Reagents Kit, Life Technologies Corporation, Carlsbad, CA, USA). An internal positive control (TaqMan R Exogenous Internal Positive Control Reagents, Life Technologies Corporation, Carlsbad, CA, USA) is used to detect PCR inhibitors. In February 2014, the laboratory of Rennes University Hospital was confronted with a false-negative result of P. jirovecii detection. Indeed P. jirovecii cysts were detected by microscopic examination of a bronchoalveolar lavage (BAL) specimen from a human immunodeficiency virus (HIV)-infected patient developing overt clinical and radiological PCP, whereas the real-time PCR assay, as described above, was negative. This result was confirmed by two other runs of which one was performed in another laboratory at Brest University Hospital. Control results allowed technical validation of the runs. As a PCR run using the same primers but SYBRGreen R instead of the probe was positive, we hypothesized that the target was effectively amplified but putative mutations at the hybridization region prevented the binding of the TaqMan R MGB probe.
The objectives of the present study were to i) test this hypothesis by sequencing the mtLSUrRNA gene of the P. jirovecii isolate with the false negative result, ii) estimate the frequency of the putative mutations by sequencing a number of P. jirovecii DNA isolates, and iii) assess their potential impact in the routine diagnosis of PCP in France through a multicenter study.
Materials and methods
The DNA from the false-negative specimen and 149 other DNA specimens from 146 PCP patients (59 specimens from Rennes University Hospital, 50 specimens from Brest University Hospital, and 40 specimens from Amiens University Hospital) were examined for sequencing. DNA extraction was performed using a commercial kit (QIAmpDNA mini kit; Qiagen, Hilden, Germany) in Rennes and NucliSens easyMag system (bioMérieux, Marcy l'Etoile, France) in Brest and Amiens. Patients' characteristics are summarized in table 1. A 301-bp fragment of the mtLSUrRNA gene was amplified using a conventional PCR assay as described by Chabé et al. 5 and sequenced from the two strands with the dideoxy chain termination method on the 3130XL Genetic Analyzer (BigDye R terminator v1.1 cycle sequencing kit, Applied Biosystems, Foster City, CA, USA). This 301-bp fragment includes the 79-bp fragment amplified by the real-time PCR used for the routine diagnosis of PCP. Chromatograms were analyzed using Pregap and Gap software (Staden package version 2003.0-beta, Staden Group). Consensus sequences were aligned with the reference sequence (GenBank accession number M58605) deposited by Sinclair et al. 6 using the BioEdit software with the Clustal R W program. Contemporaneously, a survey was conducted to determine the frequency of use of the real-time PCR described by Totet et al. 3, 4 in France. A form was emailed to the parasitology and mycology laboratories of the French University hospitals via a mailing list (www.anofel.net) to determine which techniques they apply for PCP diagnosis and the occurrence of discrepancy between microscopy and PCR detection of P. jirovecii over a 6-year period (01/01/2009 to 21/12/2014).
Results
The sequences of the 149 P. jirovecii DNA isolates were identical to the reference sequence between positions 168 and 246 which corresponds to the 79-bp fragment amplified by the real-time PCR (Figure 1 ) 3, 4 . The sequence obtained from the remaining isolate, the one that initially led to the false-negative result, had a mutation at position 210 with a RNA gene sequence of the specimen (GenBank accession number KU693284) which led to the false-negative result using the real-time PCR by Totet et al. 3 ,4 . Hybridization regions of the primers (PCW3 and PCW4) and the probe used for this real-time PCR assay are highlighted. The 79-bp fragment which is amplified by the real-time PCR assay is located between nucleotide positions 168 and 246. A transition from C to T was observed at position 210 (indicated using an ellipse), i.e. at the hybridization region of the probe.
transition from C to T (Figure 1 ; GenBank accession number KU693284). This mutation frequency was estimated at 0.67% taking into account sequencing results. Twenty-four laboratories participated in the survey of which 23 use a PCR assay in addition to a microscopic technique for PCP diagnosis. One laboratory (University Hospital of Marseilles) uses a real-time PCR assay targeting the 18S gene. Eight laboratories (University Hospitals of Bordeaux, Clermont-Ferrand, Grenoble, Lyons, Montpellier, Nimes, Strasbourg, Toulouse) use a real-time PCR assay amplifying the msg gene as previously described by Larsen et al. 7 Fourteen laboratories use a real-time PCR assay amplifying the mtLSUrRNA gene. Three out of these 14 laboratories (University Hospitals of Lille, Paris-Saint Louis, and Tours) use the real-time PCR as described by Alanio et al. 8 , two laboratories (University Hospitals of Angers and Paris-Bichat) use a commercial PCR assay (Real Time PCR Pneumocystis jirovecii, Bioevolution), one laboratory (University Hospital of Paris-Créteil) uses a real-time PCR assay as described by Botterel et al. 9 , and eight laboratories (University Hospitals of Rennes, Brest, Amiens, Reims, Dijon, Paris-Saint Antoine, Nice, and Nantes) use the real-time PCR assay described by Totet et al., which thus appears to be one of the most used PCR assay for P. jirovecii detection in France. 3, 4 Taken together, these eight laboratories observed 356 positive results of microscopic examination, although no false negative results of the real-time PCR assay were observed, except the present case. According to the assumption that the absence of falsenegative results could be correlated with the absence of the C210T mutation, these additional data make it possible to reestimate the mutation frequency at 0.28% (1/356), 95% CI [0.23-0.33].
Discussion
To the best of our knowledge, the C210T mutation of the mtLSUrRNA gene has not been yet described, whereas other mutations at positions 81, 85, 248, and 288 are wellknown. 10, 11 Indeed, these single-base polymorphisms have been used for P. jirovecii genotyping. [10] [11] [12] [13] The primer pairs and the TaqMan R MGB probe were initially designed so that they do not hybridize on these hot spots. 3, 4 However, this newly described mutation at position 210 is located at the hybridization region of the probe, that is, between positions 202 and 221 ( Figure 1 ). This single mutation observed in this P. jirovecii specimen probably prevents the binding of the TaqMan R MGB probe due to the high stringency conditions of the amplification (temperature of hybridization, 60
• C), the small size of the probe and its high specificity due to MGB labeling. 14 Interestingly a number of authors have reported that up to 80% PCP episodes were due to a mixture of P. jirovecii genotypes. 15, 16 The fact that no detection of P. jirovecii was observed in this sample strongly suggests that Pneumocystis infection in this patient was clonal. The patient was a Caucasian female, a French citizen, without past history of travel, which does not support a putative relationship between the P. jirovecii mutant and a particular geographical location. We have checked whether the C210T mutation has an impact on the two in-house PCR assays by Botterel et al. and by Alanio et al. 8, 9 Sequences amplified by these two PCR assays were aligned with the reference sequence M58605 by Sinclair et al. 6 The PCR assay by Botterel et al. is not concerned by the C210T mutation since the amplified sequence does not include position 210. 9 The PCR assay by Alanio et al. was performed on the false negative specimen since the sequence amplified by this PCR includes position 210. 8 Despite the mutation, this specimen was correctly amplified. This result may be due to the fact that the mutation is located on the hybridization region of one of the two primers and not of the probe. Nonetheless, all PCR assays requiring MGB probes can be confronted with a false negative result due to a previously undescribed punctual mutation on the probe hybridization region. Thus the occurrence of a false-negative PCR result provides arguments for maintaining microscopic techniques combined to PCR assays to achieve PCP diagnosis, which is the usual practice in France.
Be that as it may, the potential impact of the frequency of the C210T mutation in PCP diagnosis in France remains limited. It should not call into question our PCP diagnostic approach considering the value of real-time PCR for the diagnosis of PCP related to low fungal burden specifically in immunosuppressed patients without HIV infection. 8, 9, 17 
